Clinical trials: Autoimmunity
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Immune Thrombocytopenia
Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count <30,000/µL.
- Trial name
- NCT04056195
- Testing
- SKI-O-703
- Where
- 27 sites in United States, Greece and 3 more
- Volunteers
- 61 people
- Sponsor
- Oscotec Inc.
Systemic Lupus Erythematosus
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
- Trial name
- SLE-BRAVE I (NCT03616912)
- Testing
- Baricitinib
- Where
- 184 sites in United States, Australia and 16 more
- Volunteers
- 830 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use
The purpose of this study is to see if an automated insulin management system ("study system") can safely be used at home to manage blood sugar.
- Trial name
- CTR3 (NCT02137512)
- Testing
- Closed-Loop Control System, Sensor-Augmented Pump (SAP)
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 30 people
- Sponsor
- Jaeb Center for Health Research
Arthritis, Rheumatoid
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
The primary objectives of this trial are (1) To show PK (Pharmacokinetic) similarity of BI 695500 to rituximab. (2)To establish statistical equivalence of efficacy of BI 695500 and rituximab, in patients with moderately to…
- Trial name
- NCT01682512
- Testing
- BI 695500, Rituxan®, MabThera®
- Where
- 110 sites in United States, Argentina and 15 more
- Volunteers
- 294 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
App-based Education and GOal-setting in Rheumatoid Arthritis
The purpose of this pragmatic, investigator-initiated, multicentre randomised controlled trial is to study the effectiveness and feasibility of a mobile app-based self-management intervention for patients with rheumatoid…
- Trial name
- AEGORA (NCT05888181)
- Testing
- Mobile app-based self-management intervention
- Where
- 2 sites in Belgium
- Volunteers
- 128 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rheumatoid Arthritis
Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
The purpose of this study is to examine the effects of milnacipran for the treatment of pain in rheumatoid arthritis in older adults.
- Trial name
- NCT01225991
- Testing
- Milnacipran
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Los Angeles
Type 1 Diabetes, Peripheral Neuropathy
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Diabetic neuropathy (DN) is the most common chronic complication of diabetes, affecting up to50% of individuals with type 1 diabetes (T1DM).
- Trial name
- TINSAL-T1DN (NCT02936843)
- Testing
- Salsalate
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Michigan
Multiple Sclerosis
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Primary Objective: To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing…
- Trial name
- TERIKIDS (NCT02201108)
- Testing
- Teriflunomide
- Where
- 57 sites in United States, Belgium and 20 more
- Volunteers
- 166 people
- Sponsor
- Genzyme, a Sanofi Company
Type 1 Diabetes Mellitus
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
The purpose of the study is to compare the glycemic control during and following aerobic exercise using either an open or closed-loop insulin delivery system.
- Trial name
- ePID-03 (NCT00831389)
- Testing
- Closed Loop
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medtronic MiniMed, Inc.
Parkinson's Disease, Multiple Sclerosis
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Respiratory difficulty is one of the primary factors leading to death in patients with Parkinson's Disease (PD) and Multiple Sclerosis.
- Trial name
- EMST (NCT00856518)
- Testing
- EMST
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis
- Trial name
- NCT00550043
- Testing
- INCB018424
- Where
- 15 sites in United States, Poland
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Lupus Erythematosus, Systemic
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in participants with systemic lupus…
- Trial name
- NCT02070978
- Testing
- Atacicept 75 mg, Atacicept 150 mg
- Where
- 84 sites in United States, Argentina and 15 more
- Volunteers
- 253 people
- Sponsor
- EMD Serono
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
- Trial name
- NCT01023074
- Testing
- Auditory training, MS: Control Activity
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA).
- Trial name
- NCT00065260
- Testing
- Campath-1H, r-ATG, CsA
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immunoglobulin A Nephropathy
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade.
- Trial name
- NCT02384317
- Testing
- CCX168
- Where
- 6 sites in United States, Sweden
- Volunteers
- 7 people
- Sponsor
- Amgen
Arthritis, Rheumatoid
A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients
The purpose of the study is to compare the effectiveness and safety of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have inadequate disease control on methotrexate.
- Trial name
- ARABESC (NCT02260791)
- Testing
- FKB327, Humira®
- Where
- 100 sites in United States, Bulgaria and 10 more
- Volunteers
- 728 people
- Sponsor
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
Type 1 Diabetes
Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
This study aims to compare the post-meal blood glucose values of two drugs in a "real-world" setting.
- Trial name
- NCT01621776
- Testing
- Apidra, Humalog, Novolog
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of Florida